Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (IBRX)
NASDAQ:IBRX
IBRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.28 - $10.53
Previous CloseN/A
Volume1.20M
Average Volume (3M)6.55M
Market Cap
$2.32B
Enterprise Value$2.52B
Total Cash (Recent Filing)$175.91M
Total Debt (Recent Filing)$2.47M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
May 08, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding882,466,900
10 Day Avg. Volume8,078,995
30 Day Avg. Volume6,549,452
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)156.86
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit171.00
Enterprise Value/Ebitda-9.54
Forecast
1Y Price Target
$6.08Price Target Upside131.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
ImmunityBio News
PremiumCompany Announcements
ImmunityBio Secures $75 Million in Direct Offering---
Bulls Say, Bears Say
Bulls Say
Commercial MomentumANKTIVA’s Q1 2025 revenue reached approximately $16.5 million, up 129% quarter-over-quarter, indicating strong commercial momentum.
Regulatory ProgressImmunityBio recently submitted a supplemental Biologics License Application (sBLA) to the FDA, seeking to expand ANKTIVA’s approval into the broader BCG-unresponsive papillary-only NMIBC population.
Supply Chain EnhancementThe availability of rBCG removes a key bottleneck to ANKTIVA use and provides positive momentum for ANKTIVA sales.
Bears Say
Clinical RiskRisks to achieving our price target include clinical risk where ImmunityBio’s assets may fail to demonstrate meaningful levels of efficacy in clinical trials.
Manufacturing ChallengesThe manufacturing facility's buildout is still in transition, indicating that realizing its full potential will depend on execution and timing across ongoing milestones.
---
Ownership Overview
74.13% Insiders
2.54% Mutual Funds
0.10% Other Institutional Investors
19.65% Public Companies and
Individual Investors
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $2.28 and its highest was $10.53 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $2.32B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is May 08, 2025 which is in 9 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Mar 03, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.11.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.13.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 882,466,900 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -13.374%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in IBRX
---
ImmunityBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.08 (131.18% Upside)
$6.08 (131.18% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $230.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.44%
12-Months-Change
Fundamentals
Return on Equity
78.99%
Trailing 12-Months
Asset Growth
-24.09%
Trailing 12-Months
Company Description
ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
---
IBRX Stock 12 Month Forecast
Average Price Target
$6.08
▲(131.18% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Amneal Pharmaceuticals
―
Immunovant
―
MoonLake Immunotherapeutics
―
Edgewise Therapeutics
―
---